Assessing Cardiovascular Risk in Your Patients

Now Viewing

EP: 1.Assessing Cardiovascular Risk in Your Patients

EP: 2.Matching the Intensity of Treatment to Cardiovascular Risk

EP: 3.How Low is Too Low in LDL-C?

EP: 4.Nonstatin Agents for LDL-C Lowering

EP: 5.Combination Therapy in LDL Lowering

EP: 6.Overcoming Access Barriers to Novel Non Statin Therapies

EP: 7.The Cumulative Burden of LDL-C

EP: 8.Mechanism of Action of Nonstatin Therapies

EP: 9.Clinical Trial Results on Novel Nonstatins Agents.

EP: 10.How to Select Between Available LDL-C Lowering Therapies

EP: 11.Looking Into the Future of Lipid Management

Summary

This video series, moderated by Michael Gibson, MD focused on the role of non-Stanton therapies in lowering low-density lipoprotein (LDL) cholesterol for cardiovascular risk reduction. The panel included Payal Kohli, MD, Manesh Patel, MD, and Pam Taub, MD.

Experts highlighted progress in global cardiovascular risk assessment, emphasizing LDL as a modifiable risk factor. They stressed the importance of considering factors such as hypertension, diabetes, heart failure, and metabolic factors like weight. The discussion touched on the complexity of assessing subclinical atherosclerotic cardiovascular disease.

The experts explored the need for multiple tools in risk assessment, including biomarkers, clinical history, and imaging modalities like coronary calcium scoring and computerized tomography (CT) coronary angiography. The conversation shifted to LP-A testing, with experts advocating for increased awareness and incorporation into American guidelines. The primitive stage of LP-A testing was acknowledged, but its importance as a risk factor beyond LDL was emphasized.

Experts discussed the evolving role of calcium scoring and CT angiography in diagnosing atherosclerosis, noting their potential to enhance risk assessment. He highlighted the value of plaque characterization in CTA, providing a more comprehensive view of burden.

Summary was AI-generated and edited for clarity.